INVEGA SUSTENNA® is approved for the treatment of schizoaffective disorder
INVEGA SUSTENNA® includes a range of particle sizes to deliver rapid* and sustained plasma levels over 1 month1,2
*After both starting doses.
- Smaller particles dissolve to achieve rapid plasma levels without oral supplementation during the initiation window1
- Larger particles continue to dissolve to maintain sustained plasma levels over 1 month2
For your patients living with schizophrenia, who have been adequately treated with INVEGA SUSTENNA® for 4 months, who may benefit from the longest dosing interval available, learn how to dose 4 times a year with INVEGA TRINZA® (paliperidone palmitate).3
SELECT IMPORTANT SAFETY INFORMATION FOR INVEGA TRINZA®
Contraindications: Paliperidone is contraindicated in patients with a known hypersensitivity to either paliperidone, risperidone, or to any excipients of the formulation.
References: 1. INVEGA SUSTENNA® [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; March 2018. 2. Bishara D, Taylor D. Paliperidone palmitate—a new long-acting injection for schizophrenia. Br J Clin Pharmacol. 2011;3:75-78. 3. INVEGA TRINZA® [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; March 2018.
Content area 1.2